spacer
home > white papers > Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery - Presspart Manufacturing Ltd
WHITE PAPERS
logo_Presspart_5.jpg

Presspart Manufacturing Ltd

phone +44 1254 584131
email chad.mayoh@presspart.com
web http://www.presspart.com
email Whitebirk Industrial Estate, Blackburn, BB1 5RF

Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery

Hydrofluoroalkane (HFA)-based propellants are widely used in modern metered-dose inhalers (MDIs), due to their lack hazardous and environmentally-damaging effects. However, an HFA's active pharmaceutical ingredient can interact with the canister substrate, causing deposition of the drug to the canister walls, or interact with the solution, causing degradation and resulting in increased impurity levels. Over the past few years, a number of surface coatings have been developed that can be applied to MDI canisters and valve components, to protect the contents from deposition and degradation. More recently, plasma processes have been developed to modify and improve the surface energy performance of a MDI canister. This approach has a number of advantages to alternative coatings but requires careful optimisation to ensure the highest quality finish and MDI performance. Richard Turner, Business Development Director, Presspart Manufacturing Ltd, explains.
Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Evotec Launches PanOmics Data Analysis Platform PanHunter at Bio-IT World

Hamburg, Germany, 18 October 2022: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the launch of the first commercial version of its PanOmics data analysis platform PanHunter at Bio-IT World (18-19 October in Berlin, Germany). PanHunter is Evotec’s PanOmics data access and analytics platform and was developed and used successfully internally and in industry-shaping drug discovery partnerships over many years. Evotec now makes PanHunter available to collaborators and partners as a software-as-a-service (“SaaS”) product.
More info >>


White Papers

Choosing the Right CMO for HPAPI Manufacturing

AMRI

Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem — which CMO should you pick when each is touting similar technical capabilities?
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement